Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Teladoc's product suite myStrength Complete and Primary 360 will enhance growth in the coming quarters and into 2023. With Teledoc's integration with Livongo's product features, the company is bound to soar high.

Teladoc Stock Will Break Out with New Product Features

Some of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge purchase on Thursday.

Cathie Wood's ARK Invest Buys Over 415,000 Shares of Teladoc

Financial forecasts in the company's Investor Day presentation didn't impress.

Why Teladoc Stock Slid Sharply on Thursday

There's a long runway for growth in this industry niche.

Why Teladoc Is an Exciting Disruptor

Amazon

Novavax

The way 2022 is shaping up off and on the price charts, investors may consider these three Covid stocks to buy for a healthier portfolio. The post 3 Second-Shot Covid Stocks to Buy appeared first on InvestorPlace.

3 Second-Shot Covid Stocks to Buy

Vertex Pharmaceuticals

These companies' struggles are temporary.

2 Beaten-Down Growth Stocks You Can Buy Right Now

Toast

Twilio

These stocks are trading at least 30% off their recent highs. You may want to take advantage of the sale before the next market upswing.

Buy These 3 Stocks Before Another Market Rally

Apple

Coupa Software

Robinhood

Lemonade

Trade Desk

If you're looking at the recent stock market volatility with concern, you're not alone.

Should You Change Your Investment Thesis in a Volatile Market? Advice From 3 Investors

Even beaten-down stocks can still be long-term winners.

Here's Why Investing for the Long Term Matters

Roku

Constellation Brands

Big acquisitions have helped these companies redefine their growth outlooks.

3 Companies With Stellar Acquisition Records

Pinterest

Patience can pay off handsomely when you own stakes in innovative businesses.

Want $1 Million? Invest $250,000 in These 5 Stocks and Wait 10 Years

During the pandemic, Teladoc showed great product-market fit but the price has dropped a lot. We check the facts to see if this is warranted. The Q3 2021 results for Teladoc were in line with expectations, although there are some metrics that should be monitored closely going forward.

Why Teladoc's Stock Will Rise Again

Wall Street may be underestimating this company.

Is Teladoc Stock a Smart Buy After Q3 Earnings?

Fastly

MercadoLibre

The three stocks got caught up in a tech-stock beating on Wednesday.

Why Fastly, Teladoc Health, and MercadoLibre Stocks Fell Sharply Today

TDOC has massive upside potential over the next decade.

Teladoc: 3 Big Takeaways From Q3 Results

NVIDIA

Block

Several major trends can be your friends by investing in these growth stocks.

Got $3,000? Buy These 3 Stocks Riding Unstoppable Trends

CVS Health

GoodRx Holdings

Put your money in companies that are leading the charge to transform the healthcare industry.

Got $1,000? Check Out These 3 Top Healthcare Stocks

Redfin

Short-term pain can lead to big long-term gains for opportunistic investors.

3 Discounted Growth Stocks to Buy If There's a Stock Market Crash

The telehealth leader's strong quarterly earnings helped it rebound from losses earlier this year.

Why Did Teladoc Health Climb 18% in October?

Shopify

These three companies are leaders in undeniable long-term megatrends.

3 Best Growth Stocks to Buy Right Now

Teladoc is proving to be much more than a stay-at-home stock.

This Was the Most Surprising Number From Teladoc's Q3 Results

With its current prognosis calling for another drop in price, steer clear of TDOC stock. The post With its Current Prognosis, Avoid Teladoc Stock appeared first on InvestorPlace.

With its Current Prognosis, Avoid Teladoc Stock

PURCHASE, NY, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that it will host its Investor Day on Thursday, November 18, 2021.

Teladoc Health to Host Investor Day on November 18, 2021

TDOC stock went far and fast at one point in time -- but if the trend truly is your friend, then it's probably wise to just avoid Teladoc now. The post Teladoc's Moonshot Days Are Behind It — Avoid It appeared first on InvestorPlace.

Teladoc's Moonshot Days Are Behind It — Avoid It

Teledoc stock is under selling pressure because its Livongo acquisition is hurting results and adding to an uncertain future. The post Teledoc Needs at Least a Year to Prove Itself to Investors appeared first on InvestorPlace.

News for Teladoc Stock (TDOC)